ALNY Dividende : Alnylam Pharmaceuticals Inc Analyse du rendement



Dividendes

ALNY Dividendes

Alnylam Pharmaceuticals Inc

$297.92

0.61%

$1.81

À la fermeture : May 04, 16:00:00 GMT-4

$299.42

0.5%

$1.5

Post-Marché: May 04, 20:00:00 GMT-4

Aperçu Prévision Gagner Dividendes Comptes financiers

Statistiques clés

Clôture préc.

$296.11

Prix d'ouverture

$298

Plage de la journée

$288.05 - $300.49

Plage de 52 semaines

$214.76 - $495.55

Volume

1.5M

Volume moyen

1.4M

Rendement en dividend

BPA (TTM)

2.25

Capitalisation boursière

$39.7B

Qu’est-ce que ALNY ?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.